Gubra AS (CHIX:GUBRAC) FCF Yield % : -0.43 (As of Dec. 15, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gubra AS FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Gubra AS's Trailing 12-Month Free Cash Flow is kr-50.3 Mil, and Market Cap is kr11,252.6 Mil. Therefore, Gubra AS's FCF Yield % for today is -0.43%.

The historical rank and industry rank for Gubra AS's FCF Yield % or its related term are showing as below:

CHIX:GUBRAc' s FCF Yield % Range Over the Past 10 Years
Min: -3.33 Med: -0.62 Max: 0.69
Current: -0.43

During the past 5 years, the highest FCF Yield % of Gubra AS was 0.69%. The lowest was -3.33%. And the median was -0.62%.

CHIX:GUBRAc's FCF Yield % is ranked better than
83.08% of 1507 companies
in the Biotechnology industry
Industry Median: -12.96 vs CHIX:GUBRAc: -0.43

Gubra AS's FCF Margin % for the quarter that ended in Jun. 2024 was -5.96%.

Gubra AS FCF Yield % Historical Data

The historical data trend for Gubra AS's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gubra AS FCF Yield % Chart

Gubra AS Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Gubra AS Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Yield %	Get a 7-Day Free Trial			-	-	-	-	-0.34

Competitive Comparison of Gubra AS's FCF Yield %

For the Biotechnology subindustry, Gubra AS's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gubra AS's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gubra AS's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Gubra AS's FCF Yield % falls into.

Gubra AS FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Gubra AS's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-60.615	/	0
	=	N/A%

Gubra AS's annualized FCF Yield % for the quarter that ended in Jun. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-7.191	*	2	/	4174.8992
	=	-0.34%

Gubra AS FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Gubra AS FCF Yield % Related Terms

Thank you for viewing the detailed overview of Gubra AS's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gubra AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gubra AS (CHIX:GUBRAc) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

GUBRA:Denmark PI3:Germany

Address

Horsholm Kongevej 11B, Horsholm, DNK, 2970

Website

https://www.gubra.dk

Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment.

Gubra AS Headlines

No Headlines